Hypothesis

Acarbose extends lifespan only when its microbiota‑derived SCFA surge coincides with the nocturnal feeding peak, activating hepatic GPR41/43 pathways that enhance fatty acid oxidation and autophagy. Sex differences arise because estrogen up‑regulates hepatic GPR41 expression in females, making them responsive to lower SCFA amplitudes, whereas males require a larger, precisely timed SCFA pulse. Chronic acarbose exposure induces compensatory up‑regulation of intestinal α‑glucosidase isoforms (MGAM and SI) that restore starch digestion, blunting the SCFA signal and producing the recent ITP failure in males.

Testable Predictions

1. Timing experiment – Administer acarbose either 30 min before lights‑off (night) or 30 min after lights‑on (day) to male C57BL/6J mice. Night‑treated mice will show higher colonic propionate at ZT6, increased hepatic p‑AMPK and LC3‑II, and a median lifespan extension of ~15 %; day‑treated mice will show no change.
2. Sex‑specific receptor knockout – Liver‑specific Gpr41 knockout in females will abolish the lifespan benefit of night‑timed acarbose, reducing it to male‑level efficacy, while overexpression of Gpr41 in males will rescue the night‑timed effect.
3. Enzyme compensation assay – After 8 weeks of acarbose treatment, quantitative PCR will reveal a 2‑fold increase in Mgam and Si mRNA in the proximal intestine of males but not females; co‑administration of a low‑dose MGAM/SI inhibitor will restore SCFA production and lifespan extension in males.
4. Microbiota transfer – Fecal microbiota from night‑treated, acarbose‑responsive males transplanted into germ‑deficient recipients will confer night‑time SCFA responsiveness and lifespan extension only when recipients receive acarbose at the same circadian phase.

Falsification

If night‑timed acarbose fails to raise colonic propionate or hepatic autophagy markers, or if liver Gpr41 manipulation does not shift sex‑specific outcomes, the hypothesis is refuted. Likewise, if chronic acarbose does not up‑regulate Mgam/Si or inhibiting these enzymes does not rescue the male phenotype, the compensatory enzyme mechanism is invalid.

Mechanistic Insight

The hypothesis integrates three layers: (a) circadian gating of microbial metabolite signaling, (b) hormone‑driven sex differences in hepatic SCFA sensing, and (c) adaptive enzymatic remodeling of the host that narrows the therapeutic window. It explains why historic cohorts (younger mice, ad libitum feeding) showed benefit, whereas the latest C2022 cohort—likely older, with altered feeding rhythms and higher basal α‑glucosidase expression—showed no effect in males despite identical dosing.

References

• Acarbose Life Extension in ITP Studies: https://pmc.ncbi.nlm.nih.gov/articles/PMC6567620/
• Recent March 2026 ITP Results: https://www.rapamycin.news/t/new-march-2026-itp-results-its-all-bad-news/23992
• Acarbose + Rapamycin Synergy: https://lifespan.io/news/a-drug-combo-increases-lifespan-in-mice-by-over-30/
• Mechanism of Acarbose: https://pmc.ncbi.nlm.nih.gov/articles/PMC5380489/
• Microbiota Reversibility: https://journals.asm.org/doi/10.1128/msphere.00528-18
• Species‑Specific Bacteroides Response: https://pubmed.ncbi.nlm.nih.gov/39565129/